A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration

Published:2016-01-14 Issue:9 Volume:13 Page:2941-2950
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Hutton-Smith Laurence A.¹,Gaffney Eamonn A.¹,Byrne Helen M.¹,Maini Philip K.¹,Schwab Dietmar²,Mazer Norman A.²

Affiliation:

1. Wolfson Centre For Mathematical Biology, Mathematical Institute, Andrew Wiles Building, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG, U.K.

2. Clinical Pharmacology, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Building 663/2130.12, Hochstrasse 16, 4070 Basel, Switzerland

Funder

Engineering and Physical Sciences Research Council

Medical Research Council

F. Hoffman-La Roche

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.5b00849

Reference37 articles.

2. Ranibizumab for Neovascular Age-Related Macular Degeneration